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Abstract 
 
 Antibiotics are one of the most important developments in medicine, and their 
ability to prevent and control infections has had a major impact in clinical medicine.  
However, the past three decades have shown an increase in multidrug-resistant organisms 
(MDROs) in both hospital patients and in the community, decreasing our ability to 
successfully control infection.  Complicating the depletion of effective antimicrobials is 
the fact that, in the last 10 years, there has also been a decrease in the development of 
new antibacterial agents.  Resistant infections have resulted in increased morbidity and 
mortality, with a consequential increase in healthcare costs.  The utilization of 
antimicrobial stewardship strategies in hospitals has been shown to decrease 
antimicrobial use, decrease antimicrobial resistance patterns, decrease the development of 
secondary infections, reduce adverse medication effects, and consequently decrease 
healthcare costs.  In 2007, the Infectious Diseases Society of America and the Society for 
Healthcare Epidemiology of America published the Guidelines for Developing an 
Institutional Program to Enhance Antimicrobial Stewardship, encouraging hospitals to 
implement antimicrobial stewardship programs and presenting a blueprint for their 
development. After the Guidelines were published, several surveys of current 
antimicrobial stewardship practices ensued, including ones specific to certain states, ones 
geared towards the members of certain infectious disease professional societies, and even 
one attempting to assess antimicrobial stewardship practices nationally.  For the most 
part, these surveys have found fairly widespread implementation of antimicrobial 
stewardship strategies, even in the absence of formal antimicrobial stewardship programs.  
However, these surveys have also found that barriers to implementation of stewardship 
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programs are common.  Because the Western United States has been relatively under-
represented in these surveys, this project aimed to determine to what degree hospitals in 
western states are engaging in stewardship strategies.  Additional aims were to further 
elucidate the barriers to antimicrobial stewardship, and to identify factors associated with 
the number of antimicrobial stewardship strategies in use in a facility.  A web-based 
antimicrobial stewardship survey was disseminated via email to pharmacy directors, 
medical directors, infection control professionals, and other healthcare professionals at 
general acute care and critical access hospitals in 19 states.  Responses (n=105) were 
summarized using descriptive statistics and univariate analyses of associations between 
survey respondents and hospital characteristics and the reported usage of the various 
antimicrobial stewardship strategies.   Results demonstrated the widespread use of 
antimicrobial stewardship strategies, even in spite of simultaneous reports of barriers to 
the establishment of formal antimicrobial stewardship programs. A multivariate model 
was developed via multiple linear regression, which identified six predictors of the 
number of antimicrobial stewardship strategies in use at a hospital.  This model can be 
utilized to guide the further development of antimicrobial stewardship in facilities that are 
struggling with MDROs.  
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Introduction 
Antibiotics are one of the most important developments in medicine, and their 
ability to prevent and control infections has had a major impact in surgery, transplant 
medicine, oncology, and intensive care medicine (Society for Healthcare Epidemiology 
of America [SHEA] et al., 2012).  The use of antimicrobials began in the 1930s and 
1940s with the introduction of sulfonamides, penicillin, and streptomycin (SHEA et al., 
2012).  From the 1950s onward, a large number of natural and synthetic antimicrobial 
agents became available (SHEA et al., 2012).  However, gradually, bacteria evolved 
strategies of resistance to these antimicrobials, and the antibiotics became less effective 
(SHEA et al., 2012).  The past three decades have witnessed an increase in multidrug-
resistant organisms (MDROs) in patients admitted to hospitals and in the community.  
Examples include the spread of methicillin-resistant Staphylococcus aureus (MRSA) and 
vancomycin-resistant enterococci (VRE) among patients in healthcare settings, as well as  
carbapenemase-producing Klebsiella pneumoniae and other carbapenem-resistant 
Enterobacteriaceae spp. (CRE)  (SHEA et al., 2012).  In fact, the term “panresistant” is 
unfortunately not too strong of a description for some of the most recent pathogens that 
have been isolated (SHEA et al., 2012).  As the SHEA, the Infectious Diseases Society of 
America (IDSA), and the Pediatric Infectious Diseases Society (PIDS) state in their joint 
Policy Statement, “It is ironic that in the twenty-first century we are encountering 
bacterial infections for which we have no treatment” (2012). 
Complicating the depletion of effective antimicrobials is the fact that, in the last 
10 years, there has also been a decrease in the development of new antibacterial agents 
(Boucher et al., 2009), compromising our ability to treat infectious diseases (SHEA et al., 
2012).  Resistant infections have resulted in increased morbidity and mortality, with a 
2 
 
consequential increase in healthcare costs (Cosgrove et al., 2002; Cosgrove et al., 
2003a&b; DiazGranados et al., 2005).  The major professional infectious disease 
societies have advocated a multifaceted approach to prevent and control the emergence of 
antimicrobial-resistant organisms (SHEA et al., 2012). This recommended approach 
includes ensuring that proper therapeutic agents are available, that rapid and reliable 
diagnostics are available to detect specific pathogens and to determine their antimicrobial 
susceptibilities, and that antimicrobial stewardship programs are promoted robustly 
(SHEA et al., 2012). 
Although each professional society and healthcare facility often has its own 
definition of antimicrobial stewardship, the Policy Statement authored by SHEA, IDSA, 
and PIDS defines antimicrobial stewardship as the “coordinated interventions designed to 
improve and measure the appropriate use of antimicrobial agents by promoting the 
selection of the optimal antimicrobial drug regimen including dosing, duration of therapy, 
and route of administration” (2012).  The justification for antimicrobial stewardship 
programs rests on numerous studies that have demonstrated that antimicrobial therapy 
increases the risk of acquiring resistant organisms (Lautenbach et al., 2002; Paterson et 
al., 2004; Weber et al., 2003).  This is especially troubling, given the fact that the overuse 
and inappropriate use of antimicrobials has also been reported in the literature (Dellit et 
al., 2007).  Optimizing antimicrobial use should minimize antimicrobial resistance (Drew 
et al., 2009), as well as achieve the best clinical outcome and minimize adverse events 
(SHEA et al., 2012).  Indeed, it has been reported that the implementation of 
antimicrobial stewardship strategies in acute care hospitals decreases antimicrobial use 
(by 22-36%), antimicrobial resistance patterns, development of secondary infections, and 
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adverse medication effects, consequently decreasing healthcare costs in hospital settings 
by $200,000 to $900,000 annually (Bal et al., 2011; Drew et al., 2009; Goff et al., 2011; 
Ohl et al., 2011; Pope et al., 2009).   
The goals of antimicrobial stewardship are to improve clinical outcomes, 
minimize unintended consequences of antimicrobial use (such as adverse events and the 
emergence of resistance), and reduce healthcare costs (Dellit et al., 2007; Drew et al., 
2009).  In 2007, the IDSA and SHEA published guidelines on the development of 
antimicrobial stewardship programs (Dellit et al., 2007).  These guidelines recommend 
combining effective antimicrobial stewardship with a comprehensive infection control 
program to limit the emergence and transmission of antimicrobial-resistant bacteria 
(Dellit et al., 2007).  The Guidelines for Developing an Institutional Program to Enhance 
Antimicrobial Stewardship encourage hospitals to implement antimicrobial stewardship 
programs and present a blueprint for their development (Dellit et al., 2007).   
As far as the antimicrobial stewardship team and administrative support are 
concerned, the Guidelines recommend that core members of the multidisciplinary 
antimicrobial stewardship team include an infectious diseases (ID) physician and a 
clinical pharmacist with infectious diseases (ID) training, with the inclusion of a clinical 
microbiologist, an information systems specialist, an infection control professional, and 
hospital epidemiologist being optimal.  The Guidelines also recommend collaboration 
between the antimicrobial stewardship team, hospital infection control, and pharmacy and 
therapeutics committees.  The support and collaboration of hospital administration, 
medical staff leadership, and local providers in the development and maintenance of 
antimicrobial stewardship programs is also stressed by the Guidelines, and the 
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antimicrobial stewardship team leaders should negotiate with hospital administration to 
obtain adequate authority, compensation, and expected outcomes for the program. 
 As for the elements or strategies recommended by the Guidelines, they include 
both active and supplemental antimicrobial stewardship strategies.  The active 
antimicrobial stewardship strategies include prospective audit with intervention and 
feedback, and formulary restriction/ preauthorization requirements for specific 
antimicrobial agents.  Recommended supplemental antimicrobial stewardship strategies 
include education of prescribers, evidence-based guidelines and clinical pathways, 
antimicrobial cycling with scheduled antimicrobial switch, antimicrobial order forms, 
combination therapy, streamlining or de-escalation of therapy, dose optimization, and 
conversion from parenteral to oral therapy as soon as possible.  Other supports that are 
recommended by the Guidelines include information technologies, such as electronic 
medical records (EMRs), computerized physician order entry (CPOE), clinical decision 
support, and computer-based surveillance, as well as microbiology laboratory assistance, 
such as patient-specific culture and susceptibility data, surveillance of resistant 
organisms, and molecular epidemiologic investigation of outbreaks. 
 To measure the degree of success of antimicrobial stewardship efforts, the 
Guidelines recommend monitoring process and outcome variables, where the process 
variables would include the degree to which antimicrobial use changed, and the outcome 
variables would include reduction in resistance, decreased infection rates, and lowered 
costs as a result of the process change.  
The 2012 Policy Statement on Antimicrobial Stewardship by SHEA, IDSA, and 
PIDS strongly encourages the Centers for Medicare and Medicaid Services (CMS) to 
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require healthcare institutions to develop stewardship programs (SHEA et al., 2012).   
Public reporting on healthcare-associated infections (HAIs) in healthcare settings is 
increasingly being mandated by accrediting organizations, insurance companies, and 
legislative entities (Drew et al., 2009; Trivedi et al., 2013).  For example, California 
Senate Bill (SB) 739 (Health and Safety Code §§ 1288.5–1288.9, 2006) established the 
California Department of Public Health HAI program to conduct surveillance, 
prevention, and public reporting of HAIs in general acute care hospitals in California.  In 
2008, SB 739 mandated that all general acute care hospitals develop processes for 
evaluating the judicious use of antibiotics and monitor results using appropriate quality 
improvement committees, thus providing an incentive for hospital administrators to 
establish and direct resources toward active antimicrobial stewardship programs (Drew et 
al., 2009; Trivedi et al., 2013).  Currently, California is the only U.S. state with this type 
of legislation.  Perhaps of greatest concern for hospital administrators are recent payment 
rules from CMS, where hospitals will lose a portion of their reimbursement when certain 
preventable healthcare-associated infections occur (Drew et al., 2009). 
After the Guidelines were published, surveys of antimicrobial stewardship 
practices ensued by researchers in the United States, including two surveys specific to a 
particular state (Abbo et al., 2013; Trivedi et al., 2013), one survey geared towards the 
members of certain professional societies (Pope et al., 2009), and even an attempt to 
capture the prevalence of antimicrobial stewardship practices nationally (Doron et al., 
2013).  Response rates from these surveys ranged from 7% to 53%, yielding sample sizes 
from 82 to 406 respondents (Abbo, et al., 2013; Doron, et al., 2013; Pope, et al., 2009; 
Trivedi et al., 2013).  The percentage of respondents that reported having an 
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antimicrobial stewardship program at their facility averaged around 50%, but 75%-96% 
of respondents reported the use of at least one antimicrobial stewardship strategy, with or 
without having a formal program in place (Doron, et al., 2013; Pope, et al., 2009; Trivedi 
et al., 2013). 
 The most commonly utilized antimicrobial stewardship strategies included 
prospective monitoring of antimicrobial prescribing, formulary restriction, antibiograms 
(i.e., the measurement and tracking of antimicrobial resistance), and automatic antibiotic 
stop orders (Pope et al., 2009).  Factors that have been found to be significantly 
associated with the presence of an antimicrobial stewardship program include having an 
infectious disease consultation service (Doron, et al., 2013) and having an infectious 
disease pharmacist (Doron, et al., 2013).  Barriers to antimicrobial stewardship have 
included staffing issues (Pope et al., 2009; Trivedi et al., 2013), lack of funding (Trivedi 
et al., 2013), higher-priority clinical initiatives (Pope et al., 2009), opposition from 
prescribers (Pope, et al., 2009), and resistance from hospital administration (Pope, et al., 
2009).  The Western U.S. has been relatively under-represented in these previous 
antimicrobial stewardship practice surveys.   
The aims of the present study were to assess both the current antimicrobial 
stewardship practices and the barriers to antimicrobial stewardship in general acute care 
and critical access hospitals in an under-represented portion of the United States.  This 
study also determined what percentage of hospitals are engaging in stewardship 
strategies, elucidated the barriers faced by antimicrobial stewardship programs, and 
identified factors associated with the number of antimicrobial stewardship strategies in 
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use at a facility. In addition, the following research questions and hypotheses were 
addressed. 
Research questions 
1. What percentage of hospitals in the surveyed states/regions are engaging in 
antimicrobial stewardship strategies? 
2. Which strategies and techniques are being employed in antimicrobial stewardship 
efforts in hospitals in the surveyed states/regions? 
3. What are the barriers to the overall success of antimicrobial stewardship efforts in 
hospitals in the surveyed states/regions? 
4. What factors are associated with the number of antimicrobial strategies 
implemented in hospitals in the surveyed states/regions? 
Hypothesis #1 
 Ho:  The percentage of hospitals engaging in at least one antimicrobial   
 stewardship strategy is equal among the surveyed states/regions. 
Ha:  The percentage of hospitals engaging in at least one antimicrobial 
stewardship strategy differs between the surveyed states/regions. 
This hypothesis was tested using univariate analysis of variance (ANOVA) to determine 
if the proportion of hospitals engaging in at least one stewardship strategy (continuous 
outcome variable) differed by surveyed state or region (categorical predictor variable).  
Mean differences were compared between the states/regions, and post‐hoc analyses were 
conducted when statistically significant differences between states/regions occurred. 
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Hypothesis #2 
 Ho:  The strategies being employed in antimicrobial stewardship efforts are the 
 same across the surveyed states/regions. 
 Ha:  The strategies being employed in antimicrobial stewardship efforts differ 
 between the surveyed states/regions. 
This hypothesis was analyzed using univariate analysis of variance to determine if the 
frequency of use of each antimicrobial stewardship strategy (continuous outcome 
variable) is associated with the surveyed state/region (categorical predictor variable).  
Mean differences were compared between the states/regions, and post‐hoc analyses were 
conducted when statistically significant differences between states/regions occurred. 
 
Hypothesis #3 
 Ho:  The barriers to the success of antimicrobial stewardship efforts are the same 
 across the surveyed states/regions. 
Ha:  The barriers to the success of antimicrobial stewardship efforts differ 
between the surveyed states/regions. 
This hypothesis was tested using univariate analysis of variance to compare the frequency 
of each barrier (continuous outcome variable) and surveyed state/region (categorical 
predictor variable).  Mean differences were compared between the states/regions, and 
post‐hoc analyses were conducted when statistically significant differences between 
states/regions occurred. 
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Hypothesis #4 
 Ho:  No factors are associated with the number of antimicrobial stewardship 
strategies implemented. 
 Ha:  There is at least one factor associated with the number of antimicrobial 
stewardship strategies implemented. 
This hypothesis was tested using multiple linear regression analysis to determine how 
much variance in the number of stewardship strategies implemented (continuous outcome 
variable) were accounted for by the linear combination of various continuous and 
dichotomous predictor variables (e.g., surveyed state/region, hospital type, hospital size, 
presence/absence of infectious disease consultation service, etc.). 
 
Methods 
Survey development 
The present survey (Appendix A) was modeled after that created by Doron et al., 
2013, for the national assessment of the prevalence of antimicrobial stewardship practices 
(Appendix B).  The revised survey for the present study collected information on hospital 
characteristics such as size, classification, and rurality, the presence of information 
technologies and microbiology laboratory support, the presence of a formal antimicrobial 
stewardship program, which personnel are on the antimicrobial stewardship team, the 
presence of an infectious disease consultation service and/or fellowship program, 
utilization of various antimicrobial strategies, barriers to implementation, and the process 
and outcome measures used.  Perceived degree of success from the use of antimicrobial 
stewardship strategies was also ascertained, as well as the identification of the most 
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concerning resistant organisms for each facility.  Unlike the previous surveys in the 
literature (Pope et al., 2009; Abbo et al., 2013; Doron et al., 2013; Trivedi et al., 2013), 
definitions of each antimicrobial stewardship strategy and “antimicrobial stewardship 
program” were provided in the present survey.  This study qualified for exempt status 
from the University of Nevada, Las Vegas (UNLV) Institutional Review Board, as had 
been the case for previous surveys of this nature in the literature (Doron et al., 2013; 
Trivedi et al., 2013).   
Survey distribution  
 A link to the survey was created using Qualtrics (www.qualtrics.com), and the 
survey link was disseminated through multiple waves of emails, with responses collected 
over a period of 7 weeks (from January 16, 2014, through March 7, 2014).  Several 
strategies were utilized to disseminate the survey link to relevant audiences.  One initial 
strategy was the involvement of the HAI (Healthcare Associated Infection) staff members 
of the CMS Quality Improvement Organizations (QIOs) in Alaska, Colorado, Hawaii, 
Kansas, Montana, Nebraska, New Mexico, Nevada, South Dakota, Utah, and Wyoming 
(Appendix C), to disseminate the survey link via their email lists of acute care and critical 
access hospitals in their particular state.  Another strategy was to target and message 
relevant SHEA and Association for Professionals in Infection Control and Epidemiology 
(APIC) members via membership directories (Appendix D), and the representation of the 
additional western states of Arizona, California, Idaho, North Dakota, Oklahoma, 
Oregon, Texas, and Washington were added to the sample with this strategy.   
Participation was voluntary, and various communications, such as reminders via 
email and during a webinar presentation by a Centers for Disease Control and Prevention 
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(CDC) representative, were utilized to encourage participation.  Additionally, it was 
announced in the initial messages to potential respondents that those who completed the 
survey would receive a compilation of potentially useful antimicrobial stewardship 
literature, as well as aggregated survey results, if they gave their contact information, 
which was optional.  Survey instructions specified that a single survey should be filled 
out by one professional (e.g., pharmacy director, medical director, infectious diseases 
professional, or other professional with knowledge of antimicrobial use) at each hospital.   
Data analysis 
Facilities were de-identified, and results were aggregated by state.  Respondent 
personal identifiers were only used for response clarification and the distribution of 
promised antimicrobial stewardship literature and survey results.  Responses were 
summarized using descriptive statistics.  Univariate analyses of associations between 
hospital characteristics and the reported number of antimicrobial stewardship strategies 
used were determined using t-tests, analyses of variance (ANOVAs), and 
Pearson/Spearman correlations.   Factors that were significant, with a p-value of less than 
0.1, in the univariate analyses were included in the process of building the multivariate 
model, which was analyzed using multiple linear regression (forward method).   All 
statistical analyses were performed using SPSS (v. 22).   
 
Results 
Description of sample 
 Of approximately 1000 to 1200 hospital representatives contacted (it is uncertain 
of the number contacted via each QIO’s emailing efforts), there were 110 total hospitals 
represented in the survey responses, an estimated response rate of about 9 to 11%.  Five 
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responses were from non-Western states and were excluded from analyses, leaving a total 
number of 105 responses.  Respondents represented 17 out of the 19 states targeted for 
this project; only Kansas and New Mexico were not represented.  The HAI QIO staff 
member for Kansas had requested that Kansas hospitals not be approached for this 
survey, because the Kansas QIO was concurrently conducting its own antimicrobial 
stewardship survey.  California, Nevada, and Wyoming were the most represented states 
in the sample at 21.9%, 18.1%, and 11.4%, respectively.  The representativeness of the 
sample was determined via comparison of the number of hospitals per state in the sample 
(n=105) to the number of total hospitals per state in the population (n=1639), which was 
obtained from the CMS Hospital Compare website 
(https://data.medicare.gov/data/hospital-compare; last updated 2/26/14).  The sample 
represented 6.4% of the overall number of hospitals in the surveyed states.  Further 
details regarding the states represented are included in Table 1 and Figure 1. 
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Table 1.  Number/percent/representativeness of survey respondents, by state. 
Sample (n=105) Population (n=1639) 
State # Hospitals 
% of 
Sample # Hospitals 
% Represented 
in Sample 
CA 23 21.9% 348 6.6% 
NV 19 18.1% 36 52.8% 
WY 12 11.4% 29 41.4% 
TX 9 8.6% 380 2.4% 
NE 8 7.6% 91 8.8% 
UT 6 5.7% 45 13.3% 
CO 5 4.8% 75 6.7% 
AZ 3 2.9% 78 3.8% 
MT 3 2.9% 58 5.2% 
ND 3 2.9% 45 6.7% 
OK 3 2.9% 127 2.4% 
OR 3 2.9% 60 5.0% 
WA 3 2.9% 91 3.3% 
SD 2 1.9% 55 3.6% 
AK 1 1.0% 21 4.8% 
HI 1 1.0% 17 5.9% 
ID 1 1.0% 41 2.4% 
NM 0 0.0% 42 0.0% 
TOTALS 105 100.0% 1639 6.4% 
 
 
 
Figure 1.  Geographic distribution of survey respondents, by state. 
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Since multiple states had low numbers of respondents, it was deemed necessary to group 
the states into larger units for statistical testing, and the standard U.S. Federal Regions 
were used for this purpose (http://en/wikipedia.org/wiki/File:USFederalRegions.svg). 
Table 2 and Figure 2 provide information similar to Table 1 and Figure 1, but with 
respect to Federal Regions.  Two of the regions, VI and VII, contain several states that 
were not targeted for this survey and, thus, are not represented in the sample. 
 
Table 2.  Number/percent/representativeness of survey respondents, by region. 
Sample (n=105) Population (n=2195) 
Region Number Percent # Hospitals % Represented 
VI 12 11.4% 748 1.6% 
VII 8 7.6% 448 1.8% 
VIII 31 29.5% 307 10.1% 
IX 46 43.8% 479 9.6% 
X 8 7.6% 213 3.8% 
TOTALS 105 100.0% 2195 4.8% 
Region VI: AR*, LA*, OK, NM, TX 
Region VII: IA*, MO*, KS*, NE 
Region VIII: CO, MT, ND, SD, UT, WY 
Region IX: AZ, CA, HI, NV 
Region X: AK, ID, OR, WA 
*States not approached with survey link 
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Figure 2.  Geographic distribution of survey respondents, by region. 
 
A further characterization of survey respondent and hospital characteristics can be found 
in Appendix E.  The majority of survey respondents were infection control professionals 
(57.1%), followed by pharmacy directors, infectious disease pharmacists, and other 
pharmacists (24.8% combined), infectious diseases physicians and medical directors 
(13.3% combined), and other disciplines such as hospital epidemiologists and quality 
directors (4.8%).  Of note was the representation of various hospital classifications in the 
sample.  Although general acute care hospitals (GACHs) represented 59.0% of the 
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represented 9.5%.  Regarding hospital characteristics, there was a good balance of 
hospitals that were part of multi-hospital healthcare systems (59.0%) versus independent 
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not-for-profit hospitals (68.6%), as well as teaching (47.6%) versus non-teaching 
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hospitals (52.4%).  The number of licensed beds ranged from 12 to 1000, with a mean of 
203 beds, and the number of critical care beds ranged from 0 to 150, with a mean of 24 
beds.  The number of critical care units ranged from 0 to 6, with a mean of 1.73.  Critical 
care units included mostly medical (25.7%), surgical (21.0%), mixed medical/surgical 
(67.6%), and/or cardiac (30.5%), with pediatric/neonatal (9.5%), respiratory (8.6%), 
trauma (8.6%), and burn units (1.9%) also represented in the sample. 
 Sizable portions of the survey respondents did not know their hospital’s annual 
discharges (33.3%), case mix index/CMI (88.6%), or annual antimicrobial expenditures 
(86.7%).  However, a large majority of survey respondents (82.9%) did report that they 
had access to their hospital’s antibiogram (laboratory-provided assessment of the level of 
antimicrobial resistance of isolated microorganisms).  Two-thirds of survey respondents 
(66.7%) reported that their hospital had ID physician service (either on a consultative 
basis or as actual hospital medical staff).  Almost two-thirds (60.0%) reported having a 
pharmacist assigned to manage antimicrobial prescriptions (either an ID pharmacist or 
non-specialized clinical pharmacist). 
Prevalence of antimicrobial stewardship strategy use 
 The distribution of the number of antimicrobial stewardship strategies in use in 
the overall sample is shown in Figure 3.  The distribution was relatively symmetrical with 
a slight left skew.  All respondents (100%) reported the use of at least one antimicrobial 
stewardship strategy.  The number of strategies in use ranged from 1-10, and the mean 
number of strategies used was 6.11.  The mean number of strategies in use, by state and 
by region, is shown in Tables 3 and 4, respectively.  Idaho and Alaska reported the 
highest number of strategies used, at 9.00 and 8.00, respectively; however, these two 
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states had only one respondent each.  States with means of 7.00 to 7.67 strategies used 
included Arizona, Washington, Texas, Montana, and South Dakota.  States with means of 
6.00 to 6.70 strategies used included California, Oklahoma, Nebraska, Colorado, and 
Hawaii.  The latter had only one respondent.  States with means of 5.37 to 5.67 strategies 
used included North Dakota, Utah, and Nevada.  The states with the lowest means of 
strategies used were Wyoming (4.58) and Oregon (4.33). 
 
 
Figure 3.  Number of antimicrobial stewardship strategies in use per hospital. 
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Table 3.  Mean number of antimicrobial stewardship strategies in use, by state. 
State 
# of 
hospitals Mean 
Standard 
Deviation 
ID 1 * * 
AK 1 * * 
AZ 3 7.67 1.15 
WA 3 7.67 1.15 
TX 9 7.11 1.90 
MT 3 7.00 2.00 
SD 2 7.00 1.41 
CA 23 6.70 1.43 
OK 3 6.67 2.31 
NE 8 6.13 1.46 
CO 5 6.00 0.00 
HI 1 * * 
ND 3 5.67 3.51 
UT 6 5.67 1.63 
NV 19 5.37 1.50 
WY 12 4.58 2.15 
OR 3 4.33 1.15 
Total 105 6.11 1.82 
*Unable to calculate mean/standard deviation 
 
Table 4.  Mean number of antimicrobial stewardship strategies in use, by region. 
Region N Mean 
Standard 
Deviation 
VI 12 7.00 1.91 
VII 8 6.13 1.46 
VIII 31 5.52 2.01 
IX 46 6.20 1.59 
X 8 6.63 2.13 
Total 105 6.11 1.82 
 
 The proportion of respondents reporting the use of at least one antimicrobial 
stewardship strategy was equal between regions, and the number of antimicrobial 
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stewardship strategies in use did not significantly differ by region either (p=0.139), as 
determined by ANOVA.   
Types of stewardship strategies in use 
 The percentage of survey respondents using each antimicrobial stewardship 
strategy is listed in Table 5.  Greater than three-quarters of survey respondents reported 
using dose optimization (93.3%), streamlining/de-escalation (83.8%), education of 
prescribers (79.0%), and/or antimicrobial combination therapy (79.0%).  About two-
thirds of respondents reported the use of intravenous-to-oral (IV-to-PO) conversion plans 
(69.5%) and evidence-based guidelines and pathways (64.8%).  Less than half of survey 
respondents reported the use of prospective audit (47.6%), antimicrobial order forms 
(42.9%), and formulary restriction (40.0%).  The least-used antimicrobial stewardship 
strategy was antimicrobial cycling (11.4%).   
 
Table 5. Percentage of respondents using each antimicrobial stewardship strategy. 
AS strategy* No. (%) of respondents 
Dose optimization 98 (93.3%) 
Streamlining/de-escalation 88 (83.8%) 
Prescriber education 83 (79.0%) 
Combination therapy 83 (79.0%) 
IV-to-PO conversion plan 73 (69.5%) 
Guidelines & pathways 68 (64.8%) 
Prospective audit 50 (47.6%) 
Order forms 45 (42.9%) 
Formulary restriction 42 (40.0%) 
Cycling   12 (11.4%) 
*Not mutually exclusive 
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 Regarding the results in the use of each particular antimicrobial stewardship 
strategy, also determined by ANOVA, the only significant differences found between 
regions was for formulary restriction with pre-authorization and antimicrobial order 
forms (Table 6).     
 
Table 6.  Differences in use of individual antimicrobial stewardship strategies, 
between regions. 
AS strategy   p-value 
Education of prescribers 0.374 
Formulary restriction 0.009* 
Prospective audit 
 
0.239 
Guidelines/pathways 
 
0.938 
Cycling 
  
0.844 
Order form 
 
0.041* 
Combination therapy 0.171 
Streamlining/de-escalation 0.129 
Dose optimization 
 
0.428 
IV-to-PO conversion 0.081 
*Significant at p<0.05 
  
Summary data of formulary restriction and antimicrobial order form use by region are 
shown in Tables 7 and 8, respectively.  There was a large range in the use of formulary 
restriction between regions, with 83.33% of respondents from Region VI reporting the 
use of formulary restriction at their facilities, while only 25.81% of respondents from 
Region VIII indicated use of formulary restriction.  Similarly, there was also a large 
range in the use of antimicrobial order forms betweens regions, with 75.00% of 
respondents from Region VII reporting the use of order forms at their facilities, while 
only 22.58% of respondents from Region VIII indicated use of order forms.  The results 
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of each post-hoc comparison between regions for formulary restriction and antimicrobial 
order form use are shown in Table 9 and 10, respectively. 
 
Table 7.  Formulary restriction use, by region. 
Region (N) 
No. (%) using formulary 
restriction 
VI (12) 10 (83.33%) 
VII (8) 4 (50.00%) 
X (8) 4 (50.00%) 
IX (46) 16 (34.78%) 
VIII (31) 8 (25.81%) 
Total (105) 42 (40.00%) 
 
 
Table 8.  Antimicrobial order form use, by region. 
Region (N) 
No. (%) using antimicrobial 
order forms 
VII (8) 6 (75.00)% 
VI (12) 6 (50.00%) 
IX (46) 23 (50.00%) 
X (8) 3 (37.50%) 
VIII (31) 7 (22.58)% 
Total (105) 45 (42.86%) 
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Table 9.  Differences in use of formulary restriction, between regions. 
Comparison   
Mean 
difference p-value 
VI vs. VII 0.33 0.123 
  vs. VIII 0.58 0.000* 
  vs. IX 0.49 0.002* 
  vs. X 0.33 0.123 
VII vs. VIII 0.24 0.197 
  vs. IX 0.15 0.399 
  vs. X 0.00 1.000 
VIII vs. IX -0.09 0.413 
  vs. X -0.24 0.197 
IX vs. X -0.15 0.399 
*Significant at p<0.05 
 
Table 10.  Differences in use of order forms, between regions. 
Comparison   
Mean 
difference p-value 
VI vs. VII -0.25 0.259 
  vs. VIII 0.27 0.098 
  vs. IX 0.00 1.000 
  vs. X 0.13 0.572 
VII vs. VIII 0.52 0.007* 
  vs. IX 0.25 0.179 
  vs. X 0.38 0.123 
VIII vs. IX -0.27 0.016* 
  vs. X -0.15 0.438 
IX vs. X 0.13 0.501 
*Significant at p<0.05 
 
Barriers to formal antimicrobial stewardship programs 
 Although all 105 survey respondents reported the use of at least one antimicrobial 
stewardship strategy at their hospital, only 51 respondents (48.6%) reported the presence 
of a formal antimicrobial stewardship program (ASP) at their facility (Appendix E).  Two 
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respondents (1.9%) indicated that they were uncertain if their hospital had a formal ASP.  
Of the respondents who reported not having a formal ASP (52, or 49.5%), the barriers 
indicated for not having one are listed in Table 11.  Half of the respondents noted that 
staffing constraints were a barrier.  Over one-third indicated that inadequate 
administration (38.5%) and/or prescriber support (36.5%) or not having antimicrobial 
stewardship as a clinical priority (34.6%) were barriers.  About a quarter of respondents 
indicated the barriers of inadequate information technology support (26.9%) and/or lack 
of funding (25%).  A smaller percentage of respondents (11.5% to 21.2%) noted the 
barriers to establishing a formal ASP as the lack of program leadership, not previously 
considering a formal ASP, not needing a formal ASP, and the possibility that a formal 
ASP would damage relationships with prescribers. 
 
Table 11.  Reasons listed for not having a formal antimicrobial stewardship 
program (ASP). 
Barriers to establishing a formal ASP* Number (%) 
Staffing constraints 
  
26 (50.0%) 
Inadequate administration support 20 (38.5%) 
Inadequate prescriber support 
 
19 (36.5%) 
Not a clinical priority 
 
18 (34.6%) 
Inadequate information technology support 14 (26.9%) 
Lack of funding 
  
13 (25.0%) 
No one has volunteered to lead 11 (21.2%) 
Not previously considered 
 
9 (17.3%) 
No need for a formal program 
 
7 (13.5%) 
Would damage relationships with prescribers 6 (11.5%) 
*Not mutually exclusive 
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The frequency of each of the ten reported barriers to establishing a formal ASP did not 
significantly differ by region, as analyzed by ANOVA (see Table 12 for results).  
 
Table 12.  Differences in reported barriers to implementation of a formal ASP, 
between regions. 
Barrier to ASP   p-value 
Lacking of funding 0.697 
Staffing constraints 0.951 
No leader has volunteered 0.820 
Inadequate prescriber 
support 0.998 
Inadequate admin support 0.732 
Not a clinical priority 0.574 
Inadequate info tech 
support 0.719 
Damaging MD relations 0.799 
Not previously considered 0.764 
No need for formal ASP 0.355 
 
 
Similarly, the total number of reported barriers to formal ASP establishment (with a 
possible range of 1 to 10) did not significantly differ between regions (p=0.626). 
 Factors associated with the number of AS strategies in use 
 For this study, it was found that the number of antimicrobial stewardship 
strategies in use (from 1 to 10) strongly and significantly correlated with the number of 
antimicrobial stewardship successes reported (from 1 to 7) (Spearman’s rho = +0.500; 
p<0.001).  The seven antimicrobial stewardship successes offered as choices in the 
survey were: 
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1. Improved patient outcomes 
2. Reduced infection rates 
3. Decreased antimicrobial costs 
4. Decreased antimicrobial doses prescribed 
5. Change in antimicrobial resistance patterns/Increased antimicrobial sensitivities 
6. Reduced adverse medication events 
7. Decreased secondary infections 
Univariate analyses of the association between each of 71 categorical and continuous 
survey respondent/hospital characteristics and the number of antimicrobial stewardship 
strategies in use yielded 53 significant factors with a p-value of less than 0.1.  The results 
of all 71 analyses are shown in Appendix F. 
 Of the 53 significant factors, the 37 factors (indicated by ^ in Appendix F) that 
could be considered “controllable”, or open to change with influence, were included in 
the initial regression model.  Multiple regression analysis via forward method was 
performed, resulting in 6 models with adjusted R-squares ranging from 0.296 for Model 1 
with one factor (presence of formal AS program) up to a maximum of 0.538 for Model 6 
with six factors (presence of formal AS program, use of clinical decision support, use of 
computer monitoring of antimicrobial prescriptions, presence of an antibiogram, absence 
of support from other departments, and having support from the infection 
prevention/control department).  Beta coefficients for Model 6 are listed in Table 13. 
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Table 13.  Regression model for prediction of number of antimicrobial stewardship 
strategies used. 
Coefficients 
Model 
Unstandardized 
Coefficients 
Standardized 
Coefficients 
t Sig. 
95.0% 
Confidence 
Interval for B 
B 
Std. 
Error Beta 
Lower 
Bound 
Upper 
Bound 
6 (Constant) 5.747 0.703   8.176 0.000 4.350 7.143 
AS program 1.354 0.287 0.382 4.716 0.000 0.784 1.925 
Clinical decision 
support for 
antimicrobial 
prescription/dosing 
0.989 0.320 0.230 3.093 0.003 0.354 1.624 
Antibiogram 1.081 0.358 0.232 3.020 0.003 0.370 1.792 
Computer-assisted 
monitoring of 
antimicrobial 
prescriptions 
0.765 0.325 0.178 2.357 0.021 0.120 1.410 
No support from 
other 
departments/comm
ittees 
-2.365 0.712 -0.367 -3.319 0.001 -3.780 -0.949 
Infection 
Prevention/Control -1.462 0.648 -0.251 -2.257 0.026 -2.749 -0.175 
 
 
The mathematical expression for Model 6 is shown below.  All of the six included 
variables are dichotomous and, thus, to be coded as 0 or 1. 
Number of AS strategies in use = 5.747 + 1.354 (presence of formal AS program)  
         + 0.989 (presence of clinical decision support) 
         + 1.081 (presence of antibiogram) 
          + 0.765 (presence of computer-assisted   
             prescription monitoring) 
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        – 2.365 (absence of support from other   
           departments/committees) 
        – 1.462 (presence of support from infection  
            prevention/control department) 
 
Positive predictors of the number of antimicrobial stewardship strategies in use, in order 
of decreasing strength, included the presence of a formal antimicrobial stewardship 
program (with a beta coefficient of 1.354), presence of an antibiogram (1.081), presence 
of clinical decision support to assist prescribers with appropriate antimicrobial selection 
(0.989), and presence of computer-assisted monitoring of antimicrobial prescriptions 
(0.765) (Table 15).  Negative predictors of the number of strategies included the absence 
of support from other departments or committees within the hospital (-2.365) and the 
presence of support from the infection prevention and control department, specifically (-
1.462).  As an example of how to apply the model, a hospital would be expected to be 
using 5.747 strategies to begin with.  If that hospital does not have a formal ASP(+0), but 
uses clinical decision support (+0.989), receives an antibiogram (+1.081), does not utilize 
computer-assisted prescription monitoring (+0), and has the support of other departments 
(+0), one of which is their infection control department (-1.462), one would be expect 
that hospital to be using 6.355 antimicrobial stewardship strategies.  
 
Discussion 
 The null hypotheses for Research Questions 1 and 3 were not rejected by the 
results of the analyses.  The number of respondents engaging in at least one antimicrobial 
stewardship strategy and the reported barriers to the establishment of formal 
28 
 
antimicrobial stewardship programs were the same between regions.  The null hypothesis 
for Research Question 2 was rejected at p=0.009 and p=0.041 for two of the 
antimicrobial stewardship strategies (formulary restriction and antimicrobial order forms, 
respectively) but was not rejected for the other eight strategies.  The null hypothesis for 
Research Question 4 was rejected at p<0.05 for 46 factors (with a range of p<0.001 
through p=0.046, depending on the factor tested).  Although the practice of eight of the 
antimicrobial stewardship strategies did not vary between regions, the frequency with 
which the strategies of formulary restriction and antimicrobial order forms are practiced 
did differ between regions, and there was at least one factor found to be associated with 
the number of antimicrobial stewardship strategies in place at a facility. 
 The present survey’s estimated response rate of 9-11% may seem low compared 
to the 53% and 39% response rates for the two single-state antimicrobial stewardship 
surveys in the literature (Trivedi et al., 2013; Doron et al., 2013); however, our response 
rate is comparable to the 10% and 7% response rates for the two national (i.e., multi-
state) surveys in the literature (Pope et al., 2009; Abbo et al., 2013).  Our sample size also 
fell within the range of the four previously published surveys (105 vs. 82-406).  Our 
survey respondents were more heavily weighted with infection control professionals 
(57.1% vs. 20-37%) and less weighted with pharmacists (24.8% vs. 41-80%) and 
physicians (13.3% vs. 20-28%) than the previous surveys, but were similar in proportion 
with regard to “other” disciplines, such as administrators, microbiologists, and healthcare 
epidemiologists (4.8% vs. 5-5.1%).  Most notably, our sample included a sizable portion 
of smaller, rural critical access hospitals (27.6%) in addition to general acute care 
hospitals (59.0%), owing to the size and geography of the states surveyed. 
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 The goal of the present study was to describe the antimicrobial stewardship 
practices in a sample of hospitals in the western United States and determine the factors 
associated with the number of antimicrobial stewardship strategies in use at a facility, as 
opposed to factors associated with the presence of a formal antimicrobial stewardship 
program, which has been the focus of previous studies (Pope et al., 2009; Abbo et al., 
2013; Doron et al., 2013; Trivedi et al., 2013).  Similar to the previous surveys, the 
prevalence of the use of antimicrobial stewardship strategies recommended in the 2007 
IDSA/SHEA Guidelines in this study (100%) was roughly double the prevalence of 
formally established antimicrobial stewardship programs (48.6%).  Our results also show 
that hospitals in the western U.S. are actively engaged in antimicrobial stewardship 
activities despite reporting numerous barriers to the establishment of formalized 
programs, such as staffing constraints and lack of funding.  Although California was the 
only state in the sample (and is the only state in the U.S.) with legislation mandating the 
more judicious use of antimicrobials (CA SB739), the results from this survey indicate 
that hospitals in other states throughout the west are also engaging in antimicrobial 
stewardship practices, without the necessity for a legislative mandate.  However, the 
establishment of regulatory mechanisms and reimbursement deductions such as those 
being implemented by The Joint Commission (TJC) and CMS will certainly not hurt the 
future growth of antimicrobial stewardship practices in healthcare facilities. 
 The fact that the surveyed regions did not significantly differ in the reported use 
of eight of the ten distinguishable antimicrobial stewardship strategies may demonstrate 
the success of educational outreach efforts and communications from various infectious 
disease authorities such as the CDC and the IDSA, as well as the degree to which hospital 
30 
 
staff regularly review and implement best antimicrobial use practices from the scientific 
literature.  The significant differences between regions in the reported use of formulary 
restriction and antimicrobial order forms cannot be easily explained and is a topic for 
further research, but it can be hypothesized that the regulations established by state 
payers such as Medicaid may account for these differences.   
 While the primary goal of this study was to examine the factors associated with 
the number of practices in place, the prevalence for some of the antimicrobial 
stewardship strategies inquired about in this study did somewhat vary from those found 
in previous surveys.  The prevalence of formulary restriction was 40.0% in the present 
study, similar to that in the surveys done by Pope (38%) and Trivedi (44-49%).  
However, the present study’s respondents reported a higher prevalence of prescriber 
education (79.0% vs. 31-69%) and a much higher prevalence of dose optimization 
(93.3% vs. 22-45%) and streamlining/de-escalation (83.8% vs. 4-28%) than seen in other 
studies (Pope et al., 2009; Abbo et al., 2013; Doron et al., 2013; Trivedi et al., 2013).  
This increased use of these antimicrobial stewardship strategies is likely due to the 
dedicated focus on antimicrobial stewardship in both the scientific literature and by 
infectious diseases professional societies such as APIC, IDSA, and SHEA, as the primary 
means with which to combat the increasing problem of antimicrobial resistance.  The fact 
that CMS and other healthcare payers are implementing reimbursement reductions based 
on the presence of infections within the hospital setting certainly may also be playing a 
large role in promoting the greater use of antimicrobial stewardship strategies. 
 While the totality of our sample reported the use of at least one antimicrobial 
stewardship strategy at their hospital, having a formal antimicrobial stewardship program 
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(ASP) was found to be significantly associated with the implementation of a larger 
number of strategies, which in turn was significantly related to a larger number of 
perceived “successes” reported by respondents.  Thus, the barriers to the development of 
formal ASPs deserve exploration.  Barriers to the establishment of formal ASPs are still 
present, and all barriers examined in this study were found to be universal across the 
sampled states.  The prevalence levels of some barriers in our study were comparable to 
those from previous surveys, such as staffing constraints (50% vs. 47-56%, respectively) 
and low prioritization (34.6% vs. 22-44%).  However, some barriers had greater 
prevalence in our study compared to previous surveys, notably inadequate prescriber 
support (36.5% vs. 18-32%, respectively), inadequate administration support (38.5% vs. 
14-18%), and inadequate information technology support (26.9% vs. 19%).  On a more 
positive note, some barriers showed a lower prevalence in comparison to previous 
surveys, such as lack of funding (25.0% vs. 36-69%) and lack of a willing leader for the 
program (21.2% vs. 42%).  There were also a lower percentage of respondents in this 
study (compared to other studies) who indicated that their facility had never considered 
having a formal ASP (17.3% vs. 24-37%) (Pope et al., 2009; Abbo et al., 2013; Doron et 
al., 2013; Trivedi et al., 2013).   
 As a counter to the funding barrier, there is ever-growing evidence in the 
literature that ASPs can be self-funding through the cost savings they achieve (Pope et 
al., 2009; Goff et al., 2011).  Partnerships between acute care hospitals and the rural 
critical access hospitals in the surrounding regions, as well as the involvement of quality 
and patient safety organizations such as the CMS QIOs, can be instrumental in increasing 
the prevalence of ASPs and the use of multiple antimicrobial stewardship strategies.  
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However, the more difficult task of overcoming inadequate institutional commitment to 
antimicrobial stewardship remains, and obtaining this support will be essential for the 
more widespread establishment of ASPs.   
 When evaluating what factors are associated with the number of antimicrobial 
strategies in use, the author felt it useful to differentiate between those factors deemed to 
be “unchangeable” – such as hospital classification or number of critical care units – and 
those that could be considered to be more “controllable”, or subject to influence – such as 
the presence of an antibiogram or support for stewardship by other departments and/or 
disciplines.  While it is certainly informative to posit the baseline number of 
antimicrobial stewardship strategies that might be expected for a facility based on certain 
hospital characteristics, it is perhaps even more important to predict the changes in the 
number of strategies that may occur in association with factors that are more open to 
influence.  Previous studies have examined factors associated with the presence of an 
ASP (Doron et al., 2013; Trivedi et al., 2013), but none have looked at the factors 
associated with the actual number of antimicrobial stewardship strategies in use without 
regard for whether a formalized program was present.   
 In the proposed model of “controllable” predictors in the present study, the 
presence of a formal ASP is actually one of the significant positive predictors of the 
number of stewardship strategies in use at a hospital.  The other predictors of the number 
of stewardship strategies in place at a hospital – the positive association with use of an 
antibiogram, use of clinical decision support, and use of computer-assisted monitoring of 
prescriptions, as well as the negative association with the absence of support from other 
departments -- are similarly intuitive.  However, the fact that the involvement of the 
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infection control department was a negative predictor for the number of stewardship 
strategies appears counter-intuitive.  This quizzical association might have its origins in 
the slightly different focal points of infection control versus antimicrobial stewardship.  
For infection control, the focus is on preventing initial infection and preventing the 
spread of infection that is already present; whereas, for antimicrobial stewardship, the 
focus is on the prevention of antimicrobial resistance through the appropriate use of 
antibiotics in those already infected.  Regardless, the practicality of this predictive model 
should be underscored, as it represents one of the first attempts to provide evidence-
driven direction to the many hospitals that are seeking to combat the public health issue 
of antimicrobial resistance within their facilities.  The utility of the model lies in 
application of the six factors in order to develop the infrastructure from which the 
practice of antimicrobial stewardship strategies can be more effectively supported. 
 The results of the present survey may not be generalizable to other U.S. hospitals 
due to response bias, because the sample was drawn from QIO, SHEA, and APIC 
associates; thus, the respondents might have been more likely to respond to a query 
regarding antimicrobial stewardship.  Another possible limitation of the survey was that 
there was only one spokesperson for each hospital and their opinion of the antimicrobial 
stewardship practices may have been inaccurate; however, in most cases, by virtue of 
their position/discipline at their facility, this representative would have had knowledge of 
the information required to answer the survey questions.  The survey received a fair 
degree of participation from some states, but no or very little participation from others, 
representing only 6.4% of the total number of hospitals in participating states.  
Additionally, this total number of hospitals was gleaned from the CMS Hospital Compare 
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hospital database, which identifies only hospitals that are licensed and seek 
reimbursement from Medicare.  Other limitations of this study include the self-report bias 
usually associated with surveys and the possibility of duplicate hospitals reporting 
because respondents were not required to provide facility identifiers beyond state of 
location and various hospital characteristics such as bed size.  Nevertheless, this study did 
include hospitals that were varied in their characteristics, confirmed the widespread 
implementation of antimicrobial stewardship strategies, and pointed at the challenges and 
successes that can be utilized to guide the further development of antimicrobial 
stewardship in facilities that are struggling with MDROs. 
 In conclusion, the results of this survey of antimicrobial stewardship practices in 
the Western United States have demonstrated the widespread use of stewardship 
strategies in general, as well as an increase from previous surveys in the reported usage of 
dose optimization, streamlining and de-escalation, and prescriber education in particular.  
Similar to previous surveys, there is a continuing struggle with the development of formal 
antimicrobial stewardship programs, although the barriers appear to have changed from 
lack of funding and program leadership to lack of administrator and prescriber support 
for antimicrobial stewardship.  Importantly, this survey identified several “controllable” 
predictors of antimicrobial stewardship success besides having a formal program – 
namely, the presence of an antibiogram and the necessity of support from other 
disciplines, as well as the use of information technologies such as clinical decision 
support and computer-assisted monitoring of antimicrobial prescriptions.  Future 
directions include the delineation of which antimicrobial stewardship strategies are 
associated with the greatest number of successes in terms of improved patient outcomes 
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and the further stratification of the data by general acute care versus critical access 
hospitals to assist in determining which strategies are most beneficial to each hospital 
classification. 
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Appendix A – Antimicrobial stewardship practices survey 
 
The School of Community Health Sciences, Department of Epidemiology and 
Biostatistics, at the University of Nevada, Las Vegas, is conducting this survey to assess 
current antimicrobial stewardship practices at acute care and critical access hospitals in a 
sample of states in the western U.S.  Please take 15 minutes to complete this survey, 
whether or not you feel that your hospital uses antimicrobial stewardship strategies (you 
might be surprised to find out that your hospital actually is!).  This survey is best 
completed by ONE professional (e.g. ID pharmacist, pharmacy director, ID physician, 
medical director, or infection control professional) per hospital, even if the hospital is 
part of a multi-hospital healthcare system. Responding facilities will be de-identified, and 
composite results from this survey will be returned to each participant for use in the 
continual development or initiation of antimicrobial stewardship efforts.  THANK 
YOU!!! 
 
Q1 What is your position at your hospital? 
 Infectious Diseases Pharmacist (1) 
 Pharmacy Director (2) 
 Infectious Diseases Physician (3) 
 Medical Director (4) 
 Infection Control Professional (5) 
 Other (please specify) (6) ____________________ 
 
Q2 In which state is your hospital located? ____________________ 
 
Q3 Is your hospital part of a multi-hospital healthcare system? 
 Yes (please specify how many hospitals make up the system) (1) 
____________________ 
 No (2) 
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Q4 How would you classify your hospital? 
 Rural/Critical Access (1) 
 General Acute Care (2) 
 Specialty Hospital (Cardiac, Rehab, etc.) (3) 
 Other (please specify) (4) ____________________ 
 
Q5 Is your hospital proprietary or not-for-profit? 
 Proprietary (1) 
 Not-for-profit (2) 
 Other (please specify) (3) ____________________ 
 
Q6 Is your hospital teaching or non-teaching? 
 Major physician teaching (Students, Interns, Residents, Fellows) (1) 
 Limited physician teaching (Residents, Fellows) (2) 
 Non-teaching (3) 
 Other (please specify) (4) ____________________ 
 
Q7 What is the number of licensed beds in your hospital (without Nursery)? ________ 
 
Q8 What was your hospital’s total number of discharges last calendar year? 
 Less than 100 (1) 
 Between 101 and 500 (2) 
 Between 501 and 1000 (3) 
 Between 1001 and 2000 (4) 
 Between 2001 and 4000 (5) 
 Between 4001 and 6000 (6) 
 Between 6001 and 8000 (7) 
 Between 8001 and 10,000 (8) 
 Greater than 10,000 (9) 
 I don't know (10) 
 
Q9 What is the number of designated critical care beds in your hospital? ______ 
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Q10 What type(s) of Critical Care Units does your hospital have?  Check all that apply. 
 Mixed Medical/Surgical (1) 
 Medical (2) 
 Surgical (3) 
 Cardiac Care (4) 
 Respiratory (5) 
 Burn (6) 
 Trauma (7) 
 Other (please specify) (8) ____________________ 
 
Q11 If you know the average monthly case mix index (CMI) for your hospital, please 
enter it here. 
 CMI: (1) ____________________ 
 I don't know (2) 
 
Q12 How frequently do you receive facility-specific susceptibility data (i.e. 
antibiogram)? 
 Every 6 months (1) 
 Yearly (2) 
 Other (please specify) (3) ____________________ 
 Don't receive facility-specific susceptibility data (4) 
 
Q13 Please specify the characteristics of the facility-specific antibiogram.  Check all that 
apply. 
 Provides unit-specific data also (i.e., ICU) (1) 
 Limited to organisms with >30 pathogens per cycle (2) 
 Cumulative numbers provided for organisms with  <30 pathogens per cycle (3) 
 None of these characteristics (4) 
 Don't receive a facility-specific antibiogram (5) 
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Q14 Does your microbiology laboratory provide individualized patient-specific 
susceptibility data in addition to culture results? 
 Yes (1) 
 No (2) 
 I don't know (3) 
 
Q15 Does your microbiology laboratory provide Minimum Inhibitory Concentration 
(MIC) results when reporting patient-specific susceptibility data, in addition to the 
classifications of Sensitive, Intermediate, Resistant? 
 Yes (1) 
 No (2) 
 I don't know (3) 
 
Q16 What is the total yearly antimicrobial expenditure (antibacterials and antifungals 
only) at your hospital? 
 Annual antimicrobial expenditure: (1) ____________________ 
 I don't know (2) 
 
Q17 What percent of your hospital’s total inpatient pharmacy drug budget is represented 
by antimicrobials (antibacterials and antifungals only)? 
 Less than 10% (1) 
 Between 10% and 20% (2) 
 Between 21% and 30% (3) 
 Between 31% and 50% (4) 
 Greater than 50% (5) 
 I don't know (6) 
 
Q18 Does your hospital have an Infectious Disease specialty physician-based service? 
 Yes, but it is consult only (1) 
 Yes, the physicians are paid hospital staff (i.e., employees of hospital) (2) 
 No (3) 
 I don't know (4) 
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Q19 Does your hospital have a pharmacist assigned to manage antimicrobials? 
 Yes, and they are board-certified in Infectious Diseases Pharmacy (1) 
 Yes, but they are NOT board-certified in Infectious Diseases Pharmacy (2) 
 No (3) 
 I don't know (4) 
 
Q20 Does your hospital have an Infectious Disease specialty physician fellowship 
training program? 
 Yes (1) 
 No (2) 
 I don't know (3) 
 
Q21 Which of the following techniques are utilized in your hospital to educate 
physicians/prescribers about the appropriate prescription of antimicrobials?  Check all 
that apply. 
 Newsletter/Written guidelines (1) 
 Email alerts (2) 
 Grand Rounds for students/house staff (3) 
 Conference presentations (4) 
 Webinars (5) 
 Other (please specify) (6) ____________________ 
 No formal education of prescribers has been done (7) 
 
Q22 Does your institution utilize any of the following antimicrobial restriction methods? 
Check all that apply. 
 Specific antimicrobials are only dispensed after approval is obtained (also known as 
"formulary restriction with preauthorization") (1) 
 Antimicrobials are dispensed but subject to future review with recommendations (also 
known as "prospective audit with feedback and/or intervention") (2) 
 Infectious Disease consult required (3) 
 None (4) 
 Other (please specify) (5) ____________________ 
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Q23 Who is responsible for providing the approval for restricted antibiotics? Check all 
that apply. 
 Infectious Diseases physician (1) 
 Infectious Diseases pharmacist (2) 
 Infectious Diseases fellow (3) 
 Other (please specify) (4) ____________________ 
 I don't know (5) 
 Don't utilize formulary restriction and preauthorization (6) 
 
Q24 Who is responsible for reviewing antimicrobial prescriptions and making 
recommendations?  Check all that apply. 
 Infectious Diseases physician (1) 
 Infectious Diseases pharmacist (2) 
 Infectious Diseases fellow (3) 
 Other (please specify) (4) ____________________ 
 I don't know (5) 
 Don't utilize prospective audit with feedback and/or intervention (6) 
 
Q25 Does your facility have a designated group (e.g. Pharmacy &Therapeutics 
committee or special subcommittee) that determines formulary restrictions? 
 Yes (please specify the committee or discipline) (1) ____________________ 
 No (2) 
 I don't know (3) 
 
Q26 Does your hospital utilize institutional evidence-based practice guidelines and 
clinical pathways that incorporate local resistance patterns when making decisions with 
regard to antimicrobial prescription? 
 Yes (1) 
 No (2) 
 I don't know (3) 
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Q27 Does your hospital utilize antimicrobial cycling, or the periodic substitution of a 
specific antimicrobial class for another, in order to prevent antimicrobial resistance? 
 Yes (1) 
 No (2) 
 I don't know (3) 
 
Q28 Does your hospital utilize antimicrobial order forms (with built-in automatic stop 
orders and/or physician justification requirements) in the antimicrobial prescription 
process? 
 Yes (1) 
 No (2) 
 I don't know (3) 
 
Q29 Does your hospital utilize antimicrobial combination therapy (use of multiple 
antimicrobials) for empirical initial treatment of infections in order to increase the 
breadth of coverage? 
 Yes (1) 
 No (2) 
 I don't know (3) 
 
Q30 Does your hospital utilize streamlining (switching to a more targeted narrow-
spectrum antimicrobial once an organism is identified via culture) or de-escalation 
(discontinuing the empirical antimicrobial if the culture is negative)? 
 Yes -- both streamlining and de-escalation (1) 
 Yes -- streamlining only (2) 
 Yes -- de-escalation only (3) 
 No, neither streamlining nor de-escalation (4) 
 I don't know (5) 
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Q31 Does your hospital utilize dose optimization (i.e., account for individual patient 
characteristics such as age, renal function, and weight; causative organism; site of 
infection; and pharmacodynamics of the drug) when prescribing antimicrobials? 
 Yes (1) 
 No (2) 
 I don't know (3) 
 
Q32 Does your hospital utilize a systematic plan for conversion of parenteral to oral (I.V. 
to P.O.)  administration of antimicrobials once a patient meets defined clinical criteria? 
 Yes (1) 
 No (2) 
 I don't know (3) 
 
Q33 Are you satisfied with the degree of implementation of these antimicrobial 
stewardship strategies/techniques at your hospital (i.e., actual practice)? 
 Yes (1) Somewhat (2) No (3) 
Formulary 
restriction/Preauthorization 
(1) 
      
Prospective audit with 
feedback/intervention (2) 
      
Evidence-based guidelines 
and clinical pathways (3) 
      
Antimicrobial cycling (4)       
Antimicrobial order forms 
(5) 
      
Combination therapy (6)       
Streamlining/de-escalation 
of therapy based on culture 
results (7) 
      
Dose optimization (8)       
Parenteral to oral 
conversion (9) 
      
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Q34 Are you satisfied with the outcomes/successes obtained from the implementation of 
these antimicrobial stewardship strategies/techniques at your hospital? 
 Yes (1) Somewhat (2) No (3) Not used (4) 
Formulary 
restriction/Preauthorization 
(1) 
        
Prospective audit with 
feedback/intervention (2) 
        
Evidence-based guidelines 
and clinical pathways (3) 
        
Antimicrobial cycling (4)         
Antimicrobial order forms 
(5) 
        
Combination therapy (6)         
Streamlining/de-escalation 
of therapy based on culture 
results (7) 
        
Dose optimization (8)         
Parenteral to oral 
conversion (9) 
        
 
 
Q35 What successes have you experienced at your facility as a result of the 
implementation of antimicrobial stewardship strategies?  Check all that apply. 
 Improved patient outcomes (e.g. lower mortality, decreased length of stay) (1) 
 Reduced infection rates (2) 
 Decreased antimicrobial expenditures/costs (3) 
 Decreased antimicrobial doses prescribed (4) 
 Change in antimicrobial resistance patterns/Improved antimicrobial sensitivity (5) 
 Reduced adverse medication events (6) 
 Decreased development of secondary infections (7) 
 Other (please specify) (8) ____________________ 
 Have not had success with antimicrobial stewardship strategies (9) 
 Not currently using any antimicrobial stewardship strategies (10) 
 Have not been monitoring these indicators with regard to antimicrobial stewardship 
(11) 
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Q36 What measures is your facility using to monitor antimicrobial use?  Check all that 
apply. 
 Antimicrobial purchasing/acquisition costs (1) 
 Cost of antimicrobials dispensed (2) 
 Number of antimicrobial doses prescribed (3) 
 Number of antimicrobial doses dispensed (4) 
 Defined daily dose (DDD) -- standardized calculation from World Health 
Organization (5) 
 Days of antimicrobial therapy (6) 
 Other (please specify) (7) ____________________ 
 Not measuring antimicrobial use (8) 
 
Q37 What measures is your facility using to monitor  outcomes of antimicrobial use?  
Check all that apply. 
 Antimicrobial resistance patterns (1) 
 Infection rates (2) 
 Patient outcomes such as mortality and length of stay (LOS) (3) 
 Adverse drug reactions (4) 
 Other (please specify) (5) ____________________ 
 Not measuring outcomes of antimicrobial use (6) 
 
Q38 Which microorganism is the most difficult to eradicate or control within your 
hospital? 
 Clostridium difficile (1) 
 Methicillin-resistant Staphylococcus aureus (2) 
 Vancomycin-resistant Enterococcus (3) 
 Acinetobacter baumannii (4) 
 Carbapenem-resistant Enterobacteriaceae (Escherichia coli, Klebsiella pneumoniae) 
(5) 
 Pseudomonas aeruginosa (6) 
 Proteus mirabilis (7) 
 Serratia marcescens (8) 
 Enterococcus faecium/faecalis (9) 
 Other (please specify) (10) ____________________ 
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Q48 Which microorganism is the second most difficult to eradicate or control within your 
hospital? 
 Clostridium difficile (1) 
 Methicillin-resistant Staphylococcus aureus (2) 
 Vancomycin-resistant Enterococcus (3) 
 Acinetobacter baumannii (4) 
 Carbapenem-resistant Enterobacteriaceae (Escherichia coli, Klebsiella pneumoniae 
(5) 
 Pseudomonas aeruginosa (6) 
 Proteus mirabilis (7) 
 Serratia marcescens (8) 
 Enterococcus faecium/faecalis (9) 
 Other (please specify) (10) ____________________ 
 
Q39 Do you have the active support of any of the following entities for antimicrobial 
stewardship efforts?  Check all that apply. 
 Hospital administration (1) 
 Medical staff leadership (2) 
 Physicians/prescribers (3) 
 None of these entities actively support antimicrobial stewardship (4) 
 I don't know (5) 
 
Q40 Do you have the support of other hospital departments/committees for antimicrobial 
stewardship efforts?  Check all that apply. 
 Infection Prevention/Control (1) 
 Pharmacy & Therapeutics (2) 
 Quality/Performance Improvement (3) 
 Patient Safety (4) 
 Nursing Leadership (5) 
 Microbiology Laboratory (6) 
 Information Technology (7) 
 Other (please specify) (8) ____________________ 
 No support from other departments/committees (9) 
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Q41 Which of the following information technologies are in use at your facility?  Check 
all that apply. 
 Electronic medical records (EMRs) (1) 
 Computerized physician order entry (CPOE) (2) 
 Clinical decision support for antimicrobial prescription/dosing (3) 
 Computer-based surveillance (of hospital-acquired infections, adverse medication 
events, resistance patterns) (4) 
 Computer-assisted monitoring of antimicrobial prescriptions (5) 
 Other (please specify) (6) ____________________ 
 None of these (7) 
 
Q42 Does your hospital have a formally organized and identified Antimicrobial 
Stewardship Program (ASP), in addition to utilizing various antimicrobial stewardship 
strategies? An ASP is typically defined as a multidisciplinary team officially recognized 
by hospital administration who meets regularly for the set purpose of planning and 
coordinating antimicrobial stewardship efforts to accomplish specific goals or outcomes 
for the facility. 
 Yes (1) 
 No (2) 
 I don't know (3) 
 
48 
 
Q43 What disciplines are represented on your facility’s Antimicrobial Stewardship 
Program team? Check all that apply. 
 Infectious Diseases Physician (1) 
 Other physician (2) 
 Infectious Diseases Pharmacist (3) 
 Other pharmacist (4) 
 Infection control professional (5) 
 Clinical microbiologist (6) 
 Hospital epidemiologist (7) 
 Hospital administrator (8) 
 Information technology specialist/Data analyst (9) 
 Other discipline (please specify) (10) ____________________ 
 I don't know (11) 
 Team still in development, even though we have a recognized Antimicrobial 
Stewardship Program (12) 
 Don't have a formal Antimicrobial Stewardship Program (13) 
 
Q44 How long has your facility’s Antimicrobial Stewardship Program been in place? 
 It is currently in development (1) 
 Less than 1 year (2) 
 Between 1 and 3 years (3) 
 Greater than 3 years (4) 
 I don't know (5) 
 Don't have a formal Antimicrobial Stewardship Program (6) 
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Q45 Why doesn’t your hospital have a formally organized and identified Antimicrobial 
Stewardship Program? Check all that apply. 
 Lack of funding (1) 
 Staffing constraints (2) 
 No one has volunteered to lead the program (3) 
 Insufficient physician/prescriber support of antimicrobial stewardship (4) 
 Insufficient administration support of antimicrobial stewardship (5) 
 Not high on the list of clinical priorities (6) 
 Inadequate information technology support (7) 
 Concern about damaging relationships with physicians/prescribers (8) 
 Organized program has not previously been considered (9) 
 No identified need for a formally organized program at this time (10) 
 Other (please specify) (11) ____________________ 
 We have a formal Antimicrobial Stewardship Program (12) 
 
Q46 Thank you for completing this survey! Please provide your contact information 
below. This information is optional but strongly encouraged, and will be used to clarify 
responses, obtain additional information, and return the blinded study results. Composite 
data will be shared with participants who provide contact information in order to help 
them with their practice. If you wish to receive the results of this survey and/or are 
willing to be contacted with any questions or clarifications to your responses, you MUST 
complete this section. 
Name (1) 
Email address (2) 
Phone number (3) 
Position/Title (4) 
Associated hospital/facility (5) 
 
Q47 Please feel free to share below any comments, concerns, or challenges in regard to 
antimicrobial stewardship initiatives. Be sure to click the >> button below when you are 
finished. You will then be redirected to a screen confirming that you have successfully 
completed the survey. Thank you once again!     If you have any immediate questions or 
comments, please contact Gayle Allenback at allenbac@unlv.nevada.edu. 
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Appendix B – Survey from Doron, et al., 2013 
 
In an effort to characterize antimicrobial stewardship practices in healthcare systems, the 
Division of Infectious Diseases at Tufts Medical Center is conducting this important 
survey to assess the antimicrobial stewardship methods at individual hospitals. Our goal 
is to characterize current antimicrobial practices and to better understand the efficacy and 
success of these programs.  Please take ~10 minutes to complete this national survey, the 
largest of its kind to date.  Note: this survey is best completed by ONE ID pharmacist, 
pharmacy director, or ID physician per institution. The responding institutions will be de-
identified and results from this survey will be returned to each participant for use in the 
continual development or initiation of a stewardship program. 
 
 
Section 1: Demographics 
 
1. How would you best describe your position at your facility? 
ID pharmacist 
Pharmacy Director 
ID Physician 
Other (please specify) 
 
2. How would you classify your healthcare system? 
University teaching hospital. 
University-affiliated teaching hospital. 
Non-university teaching hospital. 
Not a teaching hospital. 
Rural or critical access 
Acute/Rehab 
 
3. What is the number of licensed beds in your facility?  
Fewer than 100 
Between 101 and 300 
Between 301 and 500 
More than 500  
 
4. What is the average annual number of admissions for your healthcare facility?  
Less than 1,000 
Between 1,001 and 2,500 
Between 2,501 and 5,000  
Between 5,001 and 10,000  
More than 10,000 
 
5. What state is your institution located in?  
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State: _____________ 
 
6. If you know the average monthly case mix index for your healthcare system, 
please enter it here.  
______________                         I do not know 
 
7. Does your facility produce a cumulative susceptibility guide (i.e. antibiogram)?  
Yes 
No 
I don't know 
8. If the answer to question 7 is yes, how frequently is your cumulative susceptibility 
guide (antibiogram) produced?  
Every six months  
Yearly  
Less than yearly  
Other (please specify) 
9. If the answer to question 7 is yes, what is the publication date of your current 
cumulative susceptibility guide (antibiogram)? 
________________ 
10. Would you be willing to share specific antimicrobial purchase information in the 
future for additional analysis?  
Yes 
No 
11. What is the total yearly antimicrobial expenditure (antibacterials and 
antifungals only) at your institution?  
___________________ 
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12. What percent of the total inpatient pharmacy drug budget is represented by 
antimicrobials (antibacterials and antifungals only)?  
Less than 10%  
Between 10% and 15%  
Between 16% and 25%  
Greater than 26%  
I do not know 
13. Does your institution have an Infectious Disease consult service?  
Yes, full - time.  
Yes, part - time.  
No.  
14. If your institution has an Infectious Disease consult service, are your consultants 
any of the following? ** *.  
Private  
Hospital - based  
Combination of private and hospital based  
Other (please specify)  
15. Does your institution have a pharmacist dedicated to the management of 
antimicrobials?  
Yes  
No  
I don't know 
16. Does your institution have an antimicrobial stewardship program?  
Yes  
No  
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Section 2: Institutions with an Antimicrobial Stewardship Program 
1. If you have an antimicrobial stewardship team at your facility, who comprises it? 
Check all that apply.  
Infectious Disease Physician(s) 
 Infectious Disease Pharmacist(s)  
Clinical Microbiologist  
Information system specialist  
Infection control professional  
Hospital Epidemiologist  
We have no formal "team"  
Other (please specify) 
2. How long ago was the stewardship program put in place?  
It is in development  
It is just starting  
Less than 1 year ago  
1 - 3 years ago  
Greater than 3 years ago 
3. Is your program utilized for adults, pediatrics, or both?  
Adults only  
Pediatrics only  
Both adults and pediatrics  
4. Which of the following educational techniques are used to educate prescribers 
about appropriate prescription of antimicrobials? Check all that apply.  
Newsletter  
Email  
Grand Rounds  
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Conferences  
None  
Other (please specify) 
5. Does your institution have an ID fellowship program?  
Yes  
No 
6. If the answer to question 4 is yes, what is the level of involvement of the ID fellow 
in the antimicrobial stewardship program?  
The ID fellow approves restricted antimicrobials  
The ID fellow approves restricted antimicrobials at certain times only, e.g. nights or 
weekends  
The ID fellow does not approve restricted antimicrobials  
Other (please specify) 
7. Does your institution utilize any of the following restriction methods? Check all 
that apply. 
A "front end" approach in which specific antimicrobials are only dispensed after approval 
is obtained.  
A "back end" approach in which antimicrobials are prescribed but are subject to 
prospective audit.  
Automatic stop orders  
ID Consult required  
Verbal approval required (telephone or face to face)  
Other (please specify) 
8. If a "front end" approach is used, who is responsible for providing the approval 
for restricted antibiotics? Check all that apply.  
Physician on the Antimicrobial Stewardship team  
ID Pharmacist  
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ID Fellow  
Other (please specify) 
9. Does your institution have a specific group that approves formulary restrictions?  
No  
I do not know.  
Yes (please specify) 
10. Which of the following antimicrobial stewardship techniques are utilized by 
your institution? Check all that apply.  
Guidelines and Clinical Pathways  
Antimicrobial cycling  
Antimicrobial order forms  
Streamlining or de - escalation of therapy  
Dose optimization  
Parenteral to oral conversion  
Closed Formulary  
None  
Other (please specify)  
11. Are you satisfied with the degree to which clinicians at your institution 
streamline or de - escalate therapy based on culture data?  
Yes  
No   Please explain: 
12. Are any of the following medications or medication classes on formulary at your 
institution? Check all that apply.  
Piperacillin - Tazobactam Ticarcillin- Clavulanate Ampicillin- Sulbactam Ertapenem 
Meropenem Imipenem Doripenem Moxifloxacin Levofloxacin Ciprofloxacin 
Gatifloxacin Cefepime Ceftazidime Ceftriaxone Cefotaxime Cefoxitin Cefazolin 
Tigecycline Vancomycin Polymyxin E (Colistin) Amphotericin B Products Daptomycin 
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Linezolid Fluconazole Voriconzaole Posaconazole Micafungin Caspofungin 
Anidulafungin Other (please specify)  
13. Are there any restrictions on the following medications or medication classes? 
Check all that apply.  
Check Restricted by time, Restricted by provider, ID consult required, Other restrictions 
for the following:  
Piperacillin - Tazobactam Ticarcillin - Clavulanate Ampicillin - Sulbactam Ertapenem 
Meropenem Imipenem Doripenem Moxifloxacin Levofloxacin Ciprofloxacin 
Gatifloxacin Cefepime Ceftazidime Ceftriaxone Cefotaxime Cefoxitin Cefazolin 
Tigecycline Vancomycin Polymyxin E (Colistin) Amphotericin B Products Daptomycin 
Linezolid Fluconazole Voriconzaole Posaconazole Micafungin Caspofungin 
Anidulafungin  
Please describe other restriction methods or agents that are not on this list  
14. What is your perception of the extent to which physicians at your institution 
agree with the restrictions on antimicrobials?  
The vast majority agree.  
A small majority agree.  
The physicians are neutral.  
A small majority disagree.  
The vast majority disagree.  
I do not know. 
15. How does your institution measure the effectiveness of the antimicrobial 
stewardship program? Check all that apply.  
Antimicrobial expenditures  
Antimicrobial resistance  
Frequency of physicians' acceptance of the antimicrobial stewardship team's 
recommendations  
We do not measure the effect of the antimicrobial stewardship program  
Other (please specify) 
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16. What is your perception of the percent of the total number of requests for 
restricted antimicrobials that is denied?  
Less than 10%  
Between 10% and 25%  
Between 26% and 50%  
More than 50%  
I do not know.  
17. Does your institution use proprietary or self developed software to facilitate your 
antimicrobial stewardship program?  
No  
Self Developed  
I don't know  
Proprietary (please specify name of program). 
18. Comments/concerns/challenges.  
 
 
Section 3: Institutions without Antimicrobial Stewardship Program 
1. Has your institution ever considered having an antimicrobial stewardship 
program? If your answer is "yes", jump to question 3. If your answer is "no", 
continue on to question 2. If your answer is "I don't know" jump to question 4.  
Yes  
No  
I don't know 
2. If your institution has not ever considered having an antimicrobial stewardship 
program, why not? Check all that apply. If this question applies to you, jump to 
question 4 after you complete this question.  
Funding  
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Staffing constraints  
Insufficient medical staff buy - in  
Not high on the list of priorities  
Too many other things on the table  
Organized program has not been proposed  
Other (please specify) 
3. If your institution has considered having an antimicrobial stewardship program, 
why has it not been implemented? Check all that apply.  
Funding  
Staffing constraints  
Insufficient medical staff buy - in  
Not high on the list of priorities  
Too many other things on the table  
Organized program has not been proposed  
Other (please specify) 
4. If your institution implemented an antimicrobial stewardship program, would it 
be utilized for adults, pediatrics, or both?  
Adults only  
Pediatrics only  
Both adults and pediatrics 
5. Does a formal education program exist to educate prescribers about the 
appropriate prescription of antimicrobials?  
Yes  
No  
I do not know 
6. If the answer to question 4 is yes, which of the following educational techniques is 
utilized? Check all that apply.  
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Newsletter  
Email  
Grand Rounds  
Conferences  
Other (please specify) 
7. Does your institution have an ID fellowship program?  
Yes  
No 
8. Does your institution utilize any of the following restriction methods? Check all 
that apply.  
A "front end" approach in which specific antimicrobials are only dispensed after approval 
is obtained.  
A "back end" approach in which antimicrobials are prescribed but are subject to 
prospective audit.  
Automatic stop orders  
ID consult required  
Verbal approval required (telephone or face to face)  
None  
Other (please specify) 
9. If a "front end" approach is used, who is responsible for providing the approval 
for restricted antibiotics? Check all that apply.  
ID Physician  
ID Pharmacist  
ID Fellow  
Other (please specify) 
10. Does your institution have a specific group that approves formulary restrictions?  
No  
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I don't know.  
Yes (please specify)  
11. Please check any techniques that your institution uses with regards to 
antimicrobials.  
Guidelines and Clinical Pathways  
Antimicrobial cycling  
Antimicrobial order forms  
Streamlining or de - escalation of therapy  
Dose optimization  
Parenteral to oral conversion  
Closed Formulary  
None  
Other (please specify) 
12. Are you satisfied with the degree to which clinicians at your institution 
streamline or de - escalate therapy based on culture data?  
Yes  
No   Please explain:  
13. Are any of the following medications or medications on formulary at your 
institution? Check all that apply.  
Piperacillin - Tazobactam Ticarcillin - Clavulanate Ampicillin - Sulbactam Ertapenem 
Meropenem Imipenem Doripenem Moxifloxacin Levofloxacin Ciprofloxacin 
Gatifloxacin Cefepime Ceftazidime Ceftriaxone Cefotaxime Cefoxitin Cefazolin 
Tigecycline Vancomycin Polymyxin E (Colistin) Amphotericin B Products Daptomycin 
Linezolid Fluconazole Voriconzaole Posaconazole Micafungin Caspofungin 
Anidulafungin Other (please specify)  
14. Are there any restrictions on the following medications or medication classes? 
Check all that apply.  
Please check Restricted by time, Restricted by provider, ID consult required, Other 
restrictions for the following: 
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 Piperacillin - Tazobactam Ticarcillin - Clavulanate Ampicillin - Sulbactam Ertapenem 
Meropenem Imipenem Doripenem Moxifloxacin Levofloxacin Ciprofloxacin 
Gatifloxacin Cefepime Ceftazidime Ceftriaxone Cefotaxime Cefoxitin Cefazolin 
Tigecycline Vancomycin Polymyxin E (Colistin) Amphotericin B Products Daptomycin 
Linezolid Fluconazole Voriconzaole Posaconazole Micafungin Caspofungin 
Anidulafungin 
 Please describe other restriction methods or agents that are not on this list  
15. What is your perception of the extent to which physicians at your institution 
agree with the idea of restricting antimicrobials?  
The vast majority agree.  
A small majority agree.  
The physicians are neutral.  
A small majority disagree.  
The vast majority disagree.  
I do not know.  
 
 
Section 4: Almost done! 
1. Thank you for completing this survey! Please provide your contact information 
below. This information is optional but strongly encouraged, and will be used to 
clarify responses, obtain additional information, and return the blinded study 
results. Data will be shared with participants who provide contact information in 
order to help them with their practice. If you wish to receive the results of this 
survey and/or are willing to be contacted with any questions or clarifications to your 
responses, you MUST complete this section.  
Name:  
E- mail Address:  
Phone Number:  
Position/Title:  
Associated Institution/Facility: 
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2. Would you be interested in joining a collaboration or listserv for future discussion 
of antimicrobial stewardship programs?  
Yes  
No 
3. Are you receptive to filling out a similar follow- up questionnaire?  
 Yes  
No  
4. Please enter any comments, concerns, or challenges that you wish to share in 
regards to antimicrobial stewardship initiatives. This may include any suggestions 
for questions to be included or excluded on a future survey. Please be sure to click 
the "done" button below when you are finished. You will then be redirected to a 
screen confirming that you have successfully completed the survey. Thank you once 
again! 
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Appendix C  -- Letter to QIO HAI staff 
Dear XXXXXX, 
  
I am doing another (but larger and more in-depth) antimicrobial stewardship web-based 
survey for my thesis, and I was wondering if you can help me get the survey link 
distributed to acute care and critical access hospitals in your state.  Of course, I would 
share the results during a future webex or meeting….Participants who provide an email 
address (which is optional) will receive a compilation of useful antimicrobial stewardship 
literature as well as the aggregated survey results. 
  
Here is the text I have been using in the distribution emails: 
  
The School of Community Health Sciences, Department of Epidemiology and 
Biostatistics, at the University of Nevada, Las Vegas, is conducting a survey to assess 
current antimicrobial stewardship practices at acute care and critical access hospitals in 
a sample of states that have been previously under-represented in the Antimicrobial 
Stewardship literature. 
  
Please take 20 minutes to complete this survey, whether or not you feel that your hospital 
uses antimicrobial stewardship strategies (you might be surprised to find out that your 
hospital actually is!).  This survey is best completed by ONE professional (e.g. ID 
pharmacist, pharmacy director, ID physician, medical director, or infection control 
professional) per hospital, even if the hospital is part of a multi-hospital healthcare 
system. 
  
Responding facilities will be de-identified, and composite results from this survey, as well 
as other potentially useful Antimicrobial Stewardship literature, will be shared with each 
participant for use in the continual development or initiation of antimicrobial 
stewardship efforts.  THANK YOU!!! 
  
Click on the link below to take the survey: DUE DATE: FEBRUARY 14, 2014 
https://unlvhospitality.qualtrics.com//SE/?SID=SV_2aFXom8JDqw6swB 
  
Let me know if you can help out, or have other suggestions…  Thank you! 
 
Gayle Allenback, MS 
Infection Prevention Analyst 
Valley Health System 
gayle.allenback@uhsinc.com 
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Appendix D – Letter to APIC/SHEA members 
 
As a fellow APIC/SHEA member, I am requesting your assistance with the completion of 
a web-based Antimicrobial Stewardship practices questionnaire that I have designed for 
the thesis requirement of my MPH degree, in order to assess current Antimicrobial 
Stewardship practices at acute care and critical access hospitals in western states that 
have been previously under-represented in the Antimicrobial Stewardship literature.  
Please take a quick 15 minutes to complete this survey, whether or not your hospital uses 
antimicrobial stewardship strategies.  Many thanks! 
Copy and paste the URL below to take the survey:  
DUE DATE: MARCH 7, 2014 
https://unlvhospitality.qualtrics.com//SE/?SID=SV_2aFXom8JDqw6swB 
Gayle Allenback, MS 
Infection Prevention Analyst – Valley Health System, Las Vegas, NV 
MPH Graduate Student – University of Nevada, Las Vegas 
gayle.allenback@uhsinc.com 
allenbac@unlv.nevada.edu 
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Appendix E -- Characteristics of survey respondents 
 
Characteristic     
No. (%) of survey 
respondents 
No. of respondents     105 (100%) 
Discipline of respondents 
  
 
Infection Control Professional 
 
60 (57.1%) 
 
Pharmacy Director 
  
14 (13.3%) 
 
Infectious Diseases Physician 
 
12 (11.4%) 
 
Infectious Diseases Pharmacist 
 
7 (6.7%) 
 
Other Pharmacist 
  
5 (4.8%) 
 
Other Discipline 
  
5 (4.8%) 
  Medical Director     2 (1.9%) 
Member of multi-hospital healthcare system 
 
 
Yes 
   
62 (59.0%) 
  No       43 (41.0%) 
Hospital classification 
   
 
General acute care 
  
62 (59.0%) 
 
Rural/critical access 
  
29 (27.6%) 
 
Specialty (Cardiac, Rehab, etc.) 10 (9.5%) 
  Other       4 (3.8%) 
Hospital profit status 
   
 
Not-for-profit 
  
72 (68.6%) 
  Proprietary     32 (30.5%) 
Hospital teaching status 
  
 
Non-teaching 
  
55 (52.4%) 
  Major or minor physician/nurse teaching 50 (47.6%) 
Number of licensed beds   Range 12 - 1000, Mean 203 
Number of annual discharges 
  
 
Between 101 and 500 
 
14 (13.3%) 
 
Between 501 and 1000 
 
6 (5.7%) 
 
Between 1001 and 2000 
 
4 (3.8%) 
 
Between 2001 and 4000 
 
12 (11.4%) 
 
Between 6001 and 8000 
 
6 (5.7%) 
 
Between 8001 and 10,000 
 
2 (1.9%) 
 
Greater than 10,000 
  
22 (21.0%) 
  I don't know     35 (33.3%) 
Number of critical care beds   Range 0 -150, Mean 24 
Types of critical care units* 
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Characteristic     
No. (%) of survey 
respondents 
 
Mixed medical/surgical 
 
71 (67.6%) 
 
Cardiac care 
  
32 (30.5%) 
 
Medical 
   
27 (25.7%) 
 
Surgical 
   
22 (21.0%) 
 
Pediatric/neonatal 
  
10 (9.5%) 
 
Respiratory 
  
9 (8.6%) 
 
Trauma 
   
9 (8.6%) 
  Burn       2 (1.9%) 
Number of critical care units   Range 0 - 6, Mean 1.73 
Knowledge of average monthly case mix index 
(CMI) 
 
 
Yes 
   
12 (11.4%) 
  No       93 (88.6%) 
Receive an antibiogram (ABG) 
  
 
Yes 
   
87 (82.9%) 
  No       18 (17.1%) 
Knowledge of annual antimicrobial expenditures 
 
 
Yes 
   
14 (13.3%) 
  No       91 (86.7%) 
Have Infectious Diseases physician service 
 
 
Yes 
   
70 (66.7%) 
  No       35 (33.3%) 
Have pharmacist assigned to manage antimicrobials 
 
 
Yes 
   
63 (60.0%) 
  No       38 (36.2%) 
Have a formal antimicrobial stewardship program (ASP) 
  
 
Yes 
   
51 (48.6%) 
 
No 
   
52 (49.5%) 
  I don't know     2 (1.9%) 
* Not mutually exclusive 
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Appendix F -- Results of univariate analyses of 71 factors vs. number of 
antimicrobial stewardship strategies used 
 
Categorical variables (n=63) Significance level 
Region 0.139 
Discipline of respondent 0.287 
Multi-hospital system membership 0.001* 
Hospital classification (4 categories) 0.005* 
Acute care vs. Critical access 0.001* 
Profit status 0.202 
Teaching status 0.003* 
Number of annual discharges 0.046* 
Presence of Mixed Medical/Surgical CC unit 0.174 
Presence of Medical CC unit 0.276 
Presence of Surgical CC unit 0.041* 
Presence of Cardiac CC unit 0.786 
Presence of Respiratory CC unit 0.708 
Presence of Burn CC unit 0.140 
Presence of Trauma CC unit 0.007* 
Presence of Pediatric/Neonatal CC unit 0.003* 
Knowledge of case mix index (CMI) 0.916 
^Receive antibiogram (ABG) <0.001* 
Frequency of ABG 0.146 
^ABG provides unit-specific data 0.006* 
^ABG cumulative for isolates <30 0.093* 
^ABG provides patient-specific data 0.086* 
^Lab provides minimum inhibitory concentrations (MICs) 0.034* 
^Knowledge of annual antimicrobial expenditures 0.072* 
Percent of pharmacy budget that are antimicrobials 0.362 
Knowledge of percent of pharmacy budget 0.759 
^ID physician service present <0.001* 
^Presence of pharmacist dedicated to antimicrobials <0.001* 
^Presence of ID fellowship program 0.059* 
^Measurement of antimicrobial purchasing costs 0.009* 
^Measurement of cost of antimicrobial dispensed 0.001* 
^Measurement of # antimicrobial doses prescribed 0.083* 
^Measurement of #antimicrobial doses dispensed 0.001* 
^Measurement of defined daily dose 0.003* 
^Measurement of days of antimicrobial therapy 0.002* 
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Categorical variables (n=63) Significance level 
^Presence of antimicrobial use measures 0.004* 
Number of antimicrobial use measures 0.001* 
^Measurement of antimicrobial resistance patterns <0.001* 
^Measurement of infection rates 0.002* 
^Measurement of patient outcomes 0.041* 
^Measurement of adverse reactions 0.026* 
Number of antimicrobial outcome measures 0.003* 
^Presence of antimicrobial outcome measures 0.004* 
Most difficult microorganism to control 0.090* 
^Support of hospital administration <0.001* 
^Support of medical staff leadership <0.001* 
^Support of prescribers <0.001* 
Number of three main supports <0.001* 
^Support of infection control dept. 0.020* 
^Support of pharmacy dept. 0.002* 
^Support of quality/performance improvement dept. 0.022* 
Support of patient safety dept. 0.174 
Support of nursing leadership 0.584 
^Support of microbiology laboratory dept. <0.001* 
Support of information technology dept. 0.362 
^Presence of support of other depts. <0.001* 
Use of electronic medical records (EMRs) 0.572 
^Use of computerized physician order entry (CPOE) 0.039* 
^Use of clinical decision support <0.001* 
^Use of computer-based surveillance 0.007* 
^Computer-monitoring of antimicrobial prescriptions <0.001* 
Number of information technology supports <0.001* 
^Presence of a formal AS program <0.001* 
     Continuous variables (n=8) Significance level 
Number of hospitals in system 0.866 
Number of licensed beds <0.001* 
Number of critical care beds 0.002* 
Number of CC units 0.003* 
^Number of ABG attributes 0.003* 
Annual antimicrobial expenditures 0.501 
^Number of committee/department supports 0.001* 
^Number of information technology supports 0.035* 
* p<0.1 (n=53) 
   ^ Significant factors considered to be "controllable" (n=37) 
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Appendix G – List of abbreviations 
ABG  Antibiogram 
AK  Alaska 
ANOVA Analysis of variance 
APIC  Association for Professionals in Infection Control and Epidemiology 
AS  Antimicrobial stewardship 
ASP  Antimicrobial stewardship program 
AZ  Arizona 
CA  California 
CAH  Critical access hospital 
CC  Critical care 
CDC  Centers for Disease Control and Prevention 
CMI  Case mix index 
CMS  Centers for Medicare and Medicaid Services 
CO  Colorado 
CPOE  Computerized physician order entry 
CRE  Carbapenem-Resistant Enterobacteriaceae 
DDD  Defined daily dose 
EMR  Electronic medical record 
GACH  General acute care hospital 
HAI  Healthcare-associated infection 
HI  Hawaii 
ID  Idaho 
ID  Infectious diseases 
IDSA  Infectious Diseases Society of America 
IV-to-PO Intravenous to oral 
KS  Kansas 
MDRO  Multi-drug resistant organism 
MIC  Minimum inhibitory concentration 
MRSA  Methicillin-Resistant Staphylococcus aureus 
MT  Montana 
ND  North Dakota 
NE  Nebraska 
NM  New Mexico 
NV  Nevada 
OK  Oklahoma 
OR  Oregon 
PIDS  Pediatric Infectious Diseases Society 
QIO  Quality Improvement Organization 
SD  South Dakota 
SHEA  Society for Healthcare Epidemiology of America 
SPSS  Statistical Package for the Social Sciences 
TJC  The Joint Commission 
TX  Texas 
UNLV  University of Nevada, Las Vegas 
UT  Utah 
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VRE  Vancomycin-Resistant Enterococci 
WA  Washington 
WY  Wyoming 
  
71 
 
References 
Abbo, L., Kaming, L., Sinkowitz-Cochran, R., Burke, A.C., Hopkins, R.S., Srinivasan, 
A., & Hooton, T.M.  (June 2013).  Antimicrobial stewardship programs in 
Florida’s acute care facilities.  Infection Control and Hospital Epidemiology, 
34(6), 634-637.   DOI: 10.1086/670632 
 
Bal, A.M., & Gould, I.M.  (2011).  Antibiotic stewardship: overcoming implementation 
barriers. Curr Opin Infect Dis, 24(4), 357–362. 
 
Boucher, H.W., Talbot, G.H., Bradley, J.S., et al.  (2009).  Bad bugs, no drugs: no 
ESKAPE! An update from the Infectious Diseases Society of America.  Clinical 
Infectious Diseases, 48, 1–12. 
 
Cosgrove, S.E., & Carmeli, Y.  (2003).   The impact of antimicrobial resistance on health 
and economic outcomes.  Clinical Infectious Diseases, 36, 1433-1437. 
 
Cosgrove, S.E., Kaye, K.S., Eliopoulous, G.M., & Carmeli, Y.  (2002).  Health and 
economic outcomes of the emergence of third-generation cephalosporin resistance 
in Enterobacter species.  Archives of Internal Medicine, 162, 185–90. 
 
Cosgrove, S.E., Sakoulas, G., Perencevich, E.N., Schwaber, M.J., Karchmer, A.W., & 
Carmeli, Y.  (2003).  Comparison of mortality associated with methicillin-
resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-
analysis.  Clinical Infectious Diseases, 36, 53–9. 
 
Dellit, T.H., Owens, R.C., McGowan, J.E., Gerding, D.N., Weinstein, R.A., Burke, J.P., 
Huskins, W.C., Paterson, D.L., Fishman, N.O., Carpenter, C.F., Brennan, P.J., 
Billeter, M., & Hooton, T.M.  (January 15, 2007).  Infectious Diseases Society of 
America and the Society for Healthcare Epidemiology of America Guidelines for 
Developing an Institutional Program to Enhance Antimicrobial Stewardship. 
Clinical Infectious Diseases, 44, 159–77. 
 
DiazGranados, C.A., Zimmer, S.M., Klein, M., & Jernigan, J.A.  (2005).  Comparison of 
mortality associated with vancomycin-resistant and vancomycin-susceptible 
enterococcal bloodstream infections: a meta-analysis.  Clinical Infectious 
Diseases, 41, 327–33. 
 
72 
 
Doron, S., Nadkarni, L., Price, L.L., Lawrence, K., Davidson, L.E., Evan, J., Garber, C., 
& Snydman,  D.R.  (June 2013).  A nationwide survey of antimicrobial 
stewardship practices.  Clinical Therapeutics, 35(6), 758-785.   
 
Drew, R.H., White, R., MacDougall, C., Hermsen, E.D., & Owens, R.C.  (May 2009).  
Insights from the Society of Infectious Diseases Pharmacists on antimicrobial 
stewardship guidelines from the Infectious Diseases Society of America and the 
Society for Healthcare Epidemiology of America.  Pharmacotherapy, 29(5), 593–
607. 
 
Goff, D.A.  (2011).  Antimicrobial stewardship: bridging the gap between quality care 
and cost.  Current Opinions in Infectious Diseases, 24(suppl 1), S11–S20. 
 
Lautenbach, E., Fishman, N.O., Bilker, W.B., et al.  (2002).  Risk factors for 
fluoroquinolone resistance in nosocomial Escherichia coli and Klebsiella 
pneumoniae infections.  Archives of Internal Medicine, 162, 2469–77. 
 
Ohl, C.A., & Luther, V.P.  (2011).  Antimicrobial stewardship for inpatient facilities.  
Journal of Hospital Medicine, 6(suppl 1), S4–S15. 
 
Paterson, D.L., Ko, W.C., Von Gottberg, A., et al.  (2004).  International prospective 
study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum-
beta-lactamase production in nosocomial infections. Annals of Internal Medicine, 
140, 26–32. 
 
Pope, S.D., Dellit, T.H., Owens, R.C., & Hooton, T.M.  (January 2009).  Results of 
survey on implementation of Infectious Diseases Society of America and Society 
for Healthcare Epidemiology of America guidelines for developing an 
institutional program to enhance antimicrobial stewardship.  Infection Control and 
Hospital Epidemiology, 30(1), 97-98. 
 
Society for Healthcare Epidemiology of America, Infectious Diseases Society of 
America, & Pediatric Infectious Diseases Society.  (April 2012).  Policy statement 
on antimicrobial stewardship by the Society for Healthcare Epidemiology of 
America (SHEA), the Infectious Diseases Society of America (IDSA), and the 
Pediatric Infectious Diseases Society (PIDS).  Infection Control and Hospital 
Epidemiology,33(4), 322-327.  DOI: 10.1086/665010 
 
73 
 
Trivedi, K.K. & Rosenberg, J.  (April 2013).  The state of antimicrobial stewardship 
programs in California.  Infection Control and Hospital Epidemiology, 34(4), 
379-384.  DOI: 10.1086/669876 
 
Weber, S.G., Gold, H.S., Hooper, D.C., Karchmer, A.W., & Carmeli, Y.  (2003).  
Fluoroquinolones and the risk for methicillin-resistant Staphylococcus aureus in 
hospitalized patients.  Emerging Infectious Diseases, 9, 1415–22. 
  
74 
 
Vita 
Graduate College 
University of Nevada, Las Vegas 
 
Gayle Louise Allenback 
 
Degrees:  
 Bachelor of Arts, Psychology, 1993  
 Clemson University  
 
 Master of Science, Occupational Therapy, 1998  
 Washington University School of Medicine  
 
Research Experience/Internship: 
 Valley Health System Antimicrobial Stewardship Program (Fall 2012) 
 
Thesis Title:  A Survey of Antimicrobial Stewardship Practices in the Western United 
States: Successes and Challenges 
 
Thesis Examination Committee: 
 Co-Chair, Patricia Cruz, PhD 
 Co-Chair, Sheniz Moonie, PhD 
 Committee Member, Paulo Pinheiro, MD, PhD 
 Committee Member, Jennifer Pharr, PhD 
 Graduate College Representative, Hokwon Cho, PhD 
 
Special Honors and Awards:  
 School of Community Health Sciences Travel Award (Fall 2013)   
 
